Subject Stratification Method

About

Individuals with different metabolic phenotypes can show very different responses to the same drug treatment. If an inappropriate treatment is given, the consequences can range from lack of efficacy to serious adverse reactions. Consequently, appropriate patient stratification based on metabolic phenotype could yield significant benefits, such as improved patient outcomes and increased cost-effectiveness of drugs. We hold licensing rights for a patent for pharmacometabonomic (also known as pharmacometabolomic) phenotyping involving the use of NMR spectroscopy to provide biofluid compositional data for the modelling process. This patent relates to the identification and use of endogenous pre-treatment biomarkers or biomarker combinations that provide information on metabolic phenotype and which may potentially also be used to predict how individual subjects would respond to a potential drug treatment. This invention could be applied in areas such as personalised healthcare/stratified medicine, drug development and surveillance, and biomarker discovery. When contacting us, please quote reference number 2061.